848472-36-6

Basic information

• Product Name: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER
• Synonyms: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER;(4,6-Dimethyl-2-pyridinyl)carbamic acid tert-butyl ester;2-(Boc-amino)-4,6-dimethylpyridine;tert-Butyl (4,6-dimethyl-2-pyridinyl)carbamate
• CAS NO: 848472-36-6
• Molecular Formula: C₁₂H₁₈N₂O₂
• Molecular Weight: 222.286
• Mol File: 848472-36-6.mol
• Article Data: 6

Chemical Properties

• Melting Point: 75-79°C
• Appearance: /
• CAS DataBase Reference: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(848472-36-6)
• EPA Substance Registry System: CARBAMIC ACID, N-(4,6-DIMETHYL-2-PYRIDINYL)-,1,1-DIMETHYLETHYL ESTER(848472-36-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 848472-36-6(Hazardous Substances Data)

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 5407-87-4 2-Amino-4,6-dimethylpyridine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1018909-81-3 (3S,4S)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate 
• 1018909-82-4 (3R,4R)-tert-butyl 3-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-{(1S,4R)-4,7,7-trimethyl-3-oxo-oxabicyclo[2.2.1]heptane-1-carbonyloxy}pyrrolidine-1-carboxylate 
• 1018909-83-5 (3'S,4'S)-tert-butyl 3'-{{6''-[benzyl(tert-butoxycarbonyl)-amino]-4''-methylpyridin-2''-yl}methyl}-4'-hydroxypyrrolidine-1'carboxylate 
• 1018909-84-6 (3'R,4'R)-tert-butyl 3'-{{6''-[benzyl(tert-butoxycarbonyl)-amino]-4''-methylpyridin-2''-yl}methyl}-4'-hydroxypyrrolidine-1'carboxylate 
• 1018909-99-3 (3R,4S)-tert-butyl 3-azido-4-{{6-[benzyl(tert-butoxycarbonyl)amino]-4-methylpyridin-2-yl}methyl}-4-hydroxypyrrolidine-1-carboxylate 
• 1018910-01-4 (3R,4S)-tert-butyl 3-(2-(tert-butoxycarbonyl(3-fluorophenethyl)amino)ethylamino)-4-((6-(tert-butoxycarbonylamino)-4-methylpyridin-2-yl)methyl)pyrrolidine-1-carboxylate 
• 1386976-13-1 tert-butyl (Z)-benzyl-(6-(5-bromopent-3-en-1-yl)-4-methylpyridin-2-yl)carbamate 

Relevant articles and documents

Overcoming mutagenicity and ion channel activity: Optimization of selective spleen tyrosine kinase inhibitors

Development of a series of highly kinome-selective spleen tyrosine kinase (Syk) inhibitors with favorable druglike properties is described. Early leads were discovered through X-ray crystallographic analysis, and a systematic survey of cores within a selected chemical space focused on ligand binding efficiency. Attenuation of hERG ion channel activity inherent within the initial chemotype was guided through modulation of physicochemical properties including log D, PSA, and pKa. PSA proved most effective for prospective compound design. Further profiling of an advanced compound revealed bacterial mutagenicity in the Ames test using TA97a Salmonella strain, and subsequent study demonstrated that this mutagenicity was pervasive throughout the series. Identification of intercalation as a likely mechanism for the mutagenicity-enabled modification of the core scaffold. Implementation of a DNA binding assay as a prescreen and models in DNA allowed resolution of the mutagenicity risk, affording molecules with favorable potency, selectivity, pharmacokinetic, and off-target profiles.

Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives

Neuronal nitric oxide synthase (nNOS) represents an important therapeutic target for the prevention of brain injury and the treatment of various neurodegenerative disorders. A series of trans-substituted amino pyrrolidinomethyl 2-aminopyridine derivatives

NOS INHIBITORS FOR TREATMENT OF MOTOR DEFICIT DISORDERS

The present invention relates to preventive therapies and treatments of motor deficit disorders. In particular, the present invention relates to compositions and methods for preventative therapy and treatment of motor deficit disorders, such as cerebral p